Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00862745 · ClinicalTrials.gov registry record · Phase 4
Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 645
- Enrollment target
NCT00862745: Completed Phase 4 study, sponsored by University of California, San Francisco.
NCT00862745 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 645 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (25% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00862745, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 645 participants
- Enrollment target
Study Summary
Six hundred and thirty-six women diagnosed with urge urinary incontinence (UUI) by a three-item self-administered questionnaire (3IQ) will be randomized to 12 weeks of fesoterodine or matching placebo. The study will take place at up to 14 clinical sites in the US. All participants who complete the 12-week randomized trial will be offered open-label fesoterodine for an additional 9 months. The hypothesis of the randomized controlled trial is that among women diagnosed with urge incontinence using the 3IQ, fesoterodine is more effective than placebo in reducing the mean number of urge incontinence episodes per day.
Interventions
- DRUG Matching Placebo
- DRUG Fesoterodine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 645 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-05 |
| Phase | Phase 4 |
What the finished NCT00862745 record still lists
NCT00862745 is an interventional study that assigns participants to a tested intervention. The registered 645 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (25% higher).
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT00862745 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00862745 about?
NCT00862745 is a clinical study titled "Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)". Six hundred and thirty-six women diagnosed with urge urinary incontinence (UUI) by a three-item self-administered questionnaire (3IQ) will be randomized to 12 weeks of fesoterodine or matching placebo. The study will take place at up to 14 clinical sites in the US. All participants who complete the ...
What is the current status of trial NCT00862745?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 645 participants. The study started on 2009-01. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00862745?
The interventions under investigation include: Matching Placebo (DRUG), Fesoterodine (DRUG).
Who is sponsoring clinical trial NCT00862745?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00862745's enrollment target sits among peer trials
645 126th of 2000 higher than 1,875 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07012395 · 645 participants · Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- NCT04863222 · 646 participants · Phase 4
Clinical and Radiographic Success of MTA vs Biodentine
- NCT05146297 · 644 participants · NA
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
- NCT06994442 · 644 participants · Phase 3
Optimizing Pain Treatment in Children On Mechanical Ventilation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia